Clinical Trials Search Results

Safety, tolerability, (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors.

Ph 1 Open-Label Study Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Prelim Antitumor Activity of BGB-B455 in Pts w/Selected Adv/Met Solid Tumors

Goal of trial is to learn if experimental antibody COM701 delays progression of ovarian cancer in Relapsed PSOC. It will also learn about the safety of COM701.

Ph 3 Study of (AZD8205) Monotherapy vs MD’s Choice in Pts w/ B7-H4-Selected Adv/Met Endometrial CA Progressed On/After Platinum-Based Chemo & Anti-PD-1/Anti-PD-L1 Therapy

Ph 3 Study of First-Line Trastuzumab Deruxtecan Monotherapy vs SoC in Pts w/HER2-Expressing (IHC3+/IHC 2+), Mismatch Repair Proficient, Primary Adv/Rec Endometrial Cancer

Trial to evaluate efficacy and safety of T-DXd with bevacizumab vs bevacizumab alone as first-line maintenance therapy in HER2-expressing ovarian cancer

Ph 3, Multicenter,Randomized,Open-label Trial of Trastuzumab Deruxtecan vs SOC Chemo w/wo Radiotherapy as Adj Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Ph 2 Trial Evaluating Sapanisertib&Serabelisib (PIKTOR) w/Paclitaxel & Substudy Eval. PIKTOR w/Paclitaxel + Insulin-Suppressing Diet, in Pts w/ Adv/Rec Endometrial Cancer

Phase 3, Ran Placebo-Controlled,Double-Blind, Multicenter Trial of Selinexor in Maint. Therapy After Systemic Therapy for Pt's W/ p53 Wild-Type, Adv./Rec Endometrial Carcinoma

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer